glp-1 cv outcome trials Receptor Agonist Therapy With and Without SGLT2 Inhibitors in Patients With Type 2 Diabetes Results of cardiovascular outcome studies

GLP-1 (Version 1.0)

Continuation of Therapy If a patient is already taking a GLP-1 medication but changes insurance plans , the prior authorization can often be submitted as: Continuation of therapy Helpful documentation may include: current medication and dose duration of therapy prior weight or A1C response In some cases, continuation of therapy documentation may help bypass step therapy requirements

La evolucin de la esteatohepatitis empeora con la edad y la presencia de DM2, pero mejora con la prdida de peso: una prdida de peso superior al 10% mejora la esteatosis en el 100% de los casos, resuelve la esteatohepatitis en el 90% y revierte la fibrosis existente en al menos un estadio en el 81% de las personas17

How effective are they